FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938497258> ?p ?o ?g. }

• W2938497258 endingPage "127" @default.
• W2938497258 startingPage "119" @default.
• W2938497258 abstract "It is hypothesised that cotargeting the androgen receptor (AR) and paracrine androgen biosynthesis with enzalutamide and abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC) will dissipate adaptive feedback loops observed with either agent alone. To assess the safety, efficacy, androgen signalling/metabolome, and drug-drug interactions (DDIs) of enzalutamide with abiraterone acetate in progressive bone mCRPC (bmCRPC). This open-label, single-centre interventional study was conducted in bmCRPC patients. Enzalutamide 160 mg and abiraterone acetate 1000 mg once daily; prednisone 5 mg twice daily. Adverse events (AEs), prostate-specific antigen (PSA) response, progression-free survival (PFS), tumour biomarker/metabolite expression, and Cmin plasma concentrations were evaluated. Sixty patients were enrolled. Common AEs independent of grade/causality included fatigue (72%), hyperglycaemia (67%), alkaline phosphatase (ALP) elevation (53%), and hot flush (43%). Grade 3 AEs included hypertension (17%), alanine aminotransferase elevation (12%), ALP elevation (5%), and arthralgia (5%). No treatment-related grade 4 AEs or deaths were reported. Median treatment-discontinuation time was 312 d (95% confidence interval [CI] 196.0–483.0). Maximal PSA decline ≥50% and ≥90% occurred in 46 (77%) and 29 (48%) patients, respectively. Median PFS was 251 d (95% CI 147–337). At week 9, median tumour microenvironment androgens, precursors, and nuclear AR expression decreased (p < 0.001). The baseline tumour AR C/N terminal ratio of ≥80% was associated with treatment benefit. At enzalutamide steady state, abiraterone acetate Cmin was ∼23% lower (range 14.05–200.5 ng/ml) than when given alone. Enzalutamide combined with abiraterone acetate has a manageable safety profile, without a meaningful DDI. Both agents are pharmacodynamically active with no feedback. Efficacy findings do not support significant benefit of combined treatment for unselected bmCRPC. This is the first study combining enzalutamide plus abiraterone in bone metastatic castration-resistant prostate cancer. Results show that this combination is safe." @default.
• W2938497258 created "2019-04-25" @default.
• W2938497258 creator A5008820123 @default.
• W2938497258 creator A5021008372 @default.
• W2938497258 creator A5036272242 @default.
• W2938497258 creator A5040146877 @default.
• W2938497258 creator A5043911183 @default.
• W2938497258 creator A5048915309 @default.
• W2938497258 creator A5051529210 @default.
• W2938497258 creator A5059968050 @default.
• W2938497258 creator A5062011968 @default.
• W2938497258 creator A5062740919 @default.
• W2938497258 creator A5078910130 @default.
• W2938497258 creator A5084129032 @default.
• W2938497258 date "2020-02-01" @default.
• W2938497258 modified "2023-10-05" @default.
• W2938497258 title "Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients" @default.
• W2938497258 cites W1999742630 @default.
• W2938497258 cites W2005302422 @default.
• W2938497258 cites W2014751188 @default.
• W2938497258 cites W2015582646 @default.
• W2938497258 cites W2080134152 @default.
• W2938497258 cites W2080748037 @default.
• W2938497258 cites W2108337681 @default.
• W2938497258 cites W2110534364 @default.
• W2938497258 cites W2137467802 @default.
• W2938497258 cites W2148643283 @default.
• W2938497258 cites W2156923287 @default.
• W2938497258 cites W2164225778 @default.
• W2938497258 cites W2165782799 @default.
• W2938497258 cites W2166918329 @default.
• W2938497258 cites W2343880037 @default.
• W2938497258 cites W2519782392 @default.
• W2938497258 cites W2564702165 @default.
• W2938497258 cites W2620746860 @default.
• W2938497258 cites W2620798309 @default.
• W2938497258 cites W2889668110 @default.
• W2938497258 doi "https://doi.org/10.1016/j.euo.2019.01.008" @default.
• W2938497258 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7204265" @default.
• W2938497258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31412017" @default.
• W2938497258 hasPublicationYear "2020" @default.
• W2938497258 type Work @default.
• W2938497258 sameAs 2938497258 @default.
• W2938497258 citedByCount "19" @default.
• W2938497258 countsByYear W29384972582020 @default.
• W2938497258 countsByYear W29384972582021 @default.
• W2938497258 countsByYear W29384972582022 @default.
• W2938497258 countsByYear W29384972582023 @default.
• W2938497258 crossrefType "journal-article" @default.
• W2938497258 hasAuthorship W2938497258A5008820123 @default.
• W2938497258 hasAuthorship W2938497258A5021008372 @default.
• W2938497258 hasAuthorship W2938497258A5036272242 @default.
• W2938497258 hasAuthorship W2938497258A5040146877 @default.
• W2938497258 hasAuthorship W2938497258A5043911183 @default.
• W2938497258 hasAuthorship W2938497258A5048915309 @default.
• W2938497258 hasAuthorship W2938497258A5051529210 @default.
• W2938497258 hasAuthorship W2938497258A5059968050 @default.
• W2938497258 hasAuthorship W2938497258A5062011968 @default.
• W2938497258 hasAuthorship W2938497258A5062740919 @default.
• W2938497258 hasAuthorship W2938497258A5078910130 @default.
• W2938497258 hasAuthorship W2938497258A5084129032 @default.
• W2938497258 hasBestOaLocation W29384972582 @default.
• W2938497258 hasConcept C121608353 @default.
• W2938497258 hasConcept C126322002 @default.
• W2938497258 hasConcept C126894567 @default.
• W2938497258 hasConcept C143998085 @default.
• W2938497258 hasConcept C197934379 @default.
• W2938497258 hasConcept C2775832370 @default.
• W2938497258 hasConcept C2776551883 @default.
• W2938497258 hasConcept C2777899217 @default.
• W2938497258 hasConcept C2780192828 @default.
• W2938497258 hasConcept C61367390 @default.
• W2938497258 hasConcept C71924100 @default.
• W2938497258 hasConcept C90924648 @default.
• W2938497258 hasConcept C98274493 @default.
• W2938497258 hasConceptScore W2938497258C121608353 @default.
• W2938497258 hasConceptScore W2938497258C126322002 @default.
• W2938497258 hasConceptScore W2938497258C126894567 @default.
• W2938497258 hasConceptScore W2938497258C143998085 @default.
• W2938497258 hasConceptScore W2938497258C197934379 @default.
• W2938497258 hasConceptScore W2938497258C2775832370 @default.
• W2938497258 hasConceptScore W2938497258C2776551883 @default.
• W2938497258 hasConceptScore W2938497258C2777899217 @default.
• W2938497258 hasConceptScore W2938497258C2780192828 @default.
• W2938497258 hasConceptScore W2938497258C61367390 @default.
• W2938497258 hasConceptScore W2938497258C71924100 @default.
• W2938497258 hasConceptScore W2938497258C90924648 @default.
• W2938497258 hasConceptScore W2938497258C98274493 @default.
• W2938497258 hasIssue "1" @default.
• W2938497258 hasLocation W29384972581 @default.
• W2938497258 hasLocation W29384972582 @default.
• W2938497258 hasLocation W29384972583 @default.
• W2938497258 hasOpenAccess W2938497258 @default.
• W2938497258 hasPrimaryLocation W29384972581 @default.
• W2938497258 hasRelatedWork W1203431419 @default.
• W2938497258 hasRelatedWork W1902440608 @default.
• W2938497258 hasRelatedWork W2113899328 @default.
• W2938497258 hasRelatedWork W2309274182 @default.

• next